이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

BioMarin Pharmaceutical 배당금

배당금 기준 확인 0/6

BioMarin Pharmaceutical 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	US$1.08
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Jun 01

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

May 15

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Apr 26

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Apr 21

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 09

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Apr 18

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Mar 27

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

Jan 09

BioMarin redesigns organization, will lay off about 4% of its workforce

Oct 07

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

Sep 29

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

Sep 15

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

Aug 25

BioMarin may be an activist target after 13-F filings

Aug 15

BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth

Aug 03

BioMarin: More Growth

Jul 21

BioMarin's Solid Pipeline Bears The First Fruit

Jun 27

Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?

May 25

BioMarin: A Good Anchor For Your Biotech Portfolio

May 10

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 BMRN 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: BMRN 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

BioMarin Pharmaceutical 시장 대비 배당 수익률

BMRN 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (BMRN)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (BMRN)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BMRN 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BMRN 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BMRN 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: BMRN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

BioMarin Pharmaceutical 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 46% Undervalued

Executive VP notifies of intention to sell stock

BioMarin: Short-Term Headwinds But Long-Term Opportunities Remain

Director notifies of intention to sell stock

Biomarin Pharmaceutical Inc. Announces Positive New Data Supporting the Safety and Efficacy of VOXZOGO® (Vosoritide) in Children

Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

First quarter 2024 earnings: EPS exceeds analyst expectations

Consensus EPS estimates increase by 17%

BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc., Annual General Meeting, May 21, 2024

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Insider recently sold US$3.0m worth of stock

Insider notifies of intention to sell stock

Biomarin Announces Board Changes, Effective May 20, 2024

BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth

Full year 2023 earnings released: EPS: US$0.89 (vs US$0.76 in FY 2022)

BioMarin Pharmaceutical Inc. Provides Earnings Guidance for the Year 2024

Director notifies of intention to sell stock

BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?

Biomarin Pharmaceutical Inc. Announces Resignation of Jeffrey Ajer as Executive Vice President and Chief Commercial Officer, Effective from July 1, 2024

Director notifies of intention to sell stock

Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues

Director notifies of intention to sell stock

BioMarin Pharmaceutical Inc. Announces Board Appointments, Effective December 27, 2023

Executive VP notifies of intention to sell stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?

Biomarin Pharmaceutical Inc. Announces CEO Changes

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

BioMarin Pharmaceutical Inc. Revises Financial Guidance for the Full Year 2023

U.S. Food and Drug Administration Approves Biomarin's Voxzogo® (Vosoritide) for Children Under 5 Years with Achondroplasia

Biomarin Pharmaceutical Inc. to Present Data Showing Long-Term Benefit of Vosoritide on Growth in Children with Achondroplasia At 2023 European Society for Paediatric Endocrinology Meeting

BioMarin Pharmaceutical Inc. Announces First Person Treated with ROCTAVIAN (Valoctocogene Rxaparvovec-Rvox) for Severe Hemophilia A in Europe

Executive VP recently sold US$984k worth of stock

Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Biomarin Pharmaceutical Inc. Updates Earnings Guidance for the Year Ended December 31, 2023

We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt

Bernstein Litowitz Berger & Grossmann LLP Announces Pendency of Class Action and Proposed Settlement for Purchasers of Biomarin Pharmaceutical Inc

U.S. Food and Drug Administration Approves Biomarin's Roctavian® (Valoctocogene Rxaparvovec-Rvox) Gene Therapy for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. to Present Roctavian™ Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 13%

Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S

Independent Director notifies of intention to sell stock

These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely

Chairman & CEO notifies of intention to sell stock

Executive VP & Chief Legal Officer exercised options to buy US$148k worth of stock.

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates fall by 32%

Chairman & CEO notifies of intention to sell stock

BioMarin Pharmaceutical Inc. to Report Q4, 2022 Results on Feb 27, 2023

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Executive VP of Finance & CFO exercised options and sold US$129k worth of stock

Biomarin Pharmaceutical Inc. Announces Stable and Durable Annualized Bleed Control for Roctavian(Tm) in Large Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints At 3-Year Analysis

An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued

BioMarin Pharmaceutical Inc. Announces That the European Medicines Agency Validated Its Type II Variation Application to Extend the Indication for VOXZOGO® (Vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 2

BioMarin Pharmaceutical Inc. Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A

BioMarin Pharmaceutical Inc. Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program

BioMarin Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2022

FDA Accepts Biomarin's Biologics License Application (Bla) for Valoctocogene Roxaparvovec Aav Gene Therapy for Adults with Severe Hemophilia A

BioMarin redesigns organization, will lay off about 4% of its workforce

BioMarin Pharmaceutical Inc. to Report Q3, 2022 Results on Oct 26, 2022

BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy

BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A

BioMarin Pharmaceutical Inc. Announces First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN(TM) (valoctocogene roxaparvovec), Approved by European Commission (EC)

BioMarin to resubmit hemophilia therapy for FDA approval after EU nod

BioMarin may be an activist target after 13-F filings

Insider recently sold US$599k worth of stock

Executive VP of Finance & CFO exercised options and sold US$93k worth of stock

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations